CD274 and cancer: Immune checkpoint blockade (ICB), which reinvigorates antitumor immune responses by interrupting co-inhibitory proteins in PD-1/PD-L1/CTLA-4-related pathways, have gained great success in treating various cancers (Liebl and Hofmann, 2019; Darvin et al., 2018).